# Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

> **NCT03692442** · — · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 80 (estimated)

## Conditions studied

- Lung Cancer Non-small Cell Stage IV

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03692442
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-03-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692442, "Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03692442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*